Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent, wherein the second therapeutic agent is selected from: (a) a therapeutic agent known to modify cholinergic transmission such as M1 muscarinic receptor agonists or allosteric modulators, M2 muscarinic antagonists, acetylcholinesterase inhibitors, nicotinic receptor agonists or allosteric modulators, 5-HT4 receptor partial agonists or 5HT1A receptor antagonists and NMDA receptor antagonists or modulators, glutamate antagonists, GABA-ergic antagonists, H3 antagonists, putative metabolic/mitochondrial modulators, or disease modifying agents such as β or γ-secretase inhibitors, Tau-targeted therapeutics, β-amyloid aggregation inhibitors and β-amyloid immunotherapies; (b) an antidepressant such as a tricyclic, a MAOI (Monoamine oxidase inhibitor) a SSRI (Selective Serotonin Reuptake Inhibitor), a SNRI (Serotonin and Noradrenaline Reuptake Inhibitor) or a NaSSA (noradrenergeric and specific serotonergic antidepressant); (c) an atypical antipsychotic, for example olanzapine, clozapine, prisperidone, quentiapine, aripriprazole or paliperiden; or (d) a therapeutic agent suitable for use in Attention Deficit Disorders/Hyperactivity Syndrome, e.g. methylphenidate (Ritalin) or dexamfetamine (Dexedrine), and also the use of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof for the treatment of: a) psychiatric disorders with prominent cognitive deficits e.g. chronic PTSD (Post traumatic stress disorder); b) non-degenerative disorders with prominent cognitive deficits e.g. MS (multiple Sclerosis), post-chemotherapy, post-CABG (Coronary artery bypass graft), post-stroke; and/or c) paediatric disorders e.g. autism, mental retardation and learning disabilities.
1. A method of treating a cognitive memory disorder in a patient in need thereof comprising administering to said patient 20 to 40 mg of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an acetylcholinesterase inhibitor;
wherein said cognitive memory disorder is selected from the group consisting of Alzheimer's disease, age related cognitive decline, mild cognitive impairment, and dementia associated with mixed Alzheimer's disease and cardiovascular disease.
2. The method of claim 1 , wherein the cognitive memory disorder is Alzheimer's disease.
3. The method of claim 2 , wherein the acetylcholinesterase inhibitor is selected from donepezil, galanthamine, rivastigmine, and any combination thereof.
4. The method of claim 1 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered once a day.
5. The method of claim 1 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered more than once a day.
6. A method for improving the cognitive function of a patient suffering from Alzheimer's disease, age related cognitive decline, mild cognitive impairment, and dementia associated with mixed Alzheimer's disease and cardiovascular disease comprising administering to said patient 20 to 40 mg of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an acetylcholinesterase inhibitor.
7. The method of claim 6 , wherein the acetylcholinesterase inhibitor is selected from donepezil, galanthamine, rivastigmine, and any combination thereof.
8. A method for the treatment of a cognitive memory disorder in a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising 20 to 40 mg of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of an acetylcholinesterase inhibitor, and a pharmaceutically acceptable carrier;
wherein said cognitive memory disorder is selected from the group consisting of Alzheimer's disease, age related cognitive decline, mild cognitive impairment, and dementia associated with mixed Alzheimer's disease and cardiovascular disease.
9. The method of claim 8 , wherein the cognitive memory disorder is Alzheimer's disease.
10. The method of claim 8 , wherein the acetylcholinesterase inhibitor is selected from donepezil, galanthamine, rivastigmine, and any combination thereof.
11. The method of claim 8 , wherein the therapeutically effective amount of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, or a pharmaceutically acceptable salt thereof, is 20 to 40 mg.
12. A method for improving the cognitive function of a patient suffering from Alzheimer's disease, age related cognitive decline, mild cognitive impairment, and dementia associated with mixed Alzheimer's disease and cardiovascular disease comprising administering to said patient a pharmaceutical composition comprising 20 to 40 mg of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of an acetylcholinesterase inhibitor; and a pharmaceutically acceptable carrier.
13. The method of claim 12 , wherein the acetylcholinesterase inhibitor is selected from donepezil, galanthamine, rivastigmine, and any combination thereof.
14. The method of claim 12 , wherein the therapeutically effective amount of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, or a pharmaceutically acceptable salt thereof, is 20 to 40 mg.